Phase1/-2 study of pomalidomide in myelofibrosis

American Journal of Hematology

Volumn 85, Issue 2, 2010, Pages 129-130

  Mesa, Ruben A ^a   Pardanani, Animesh D ^b   Hussein, Kebede ^b   Wu, Wenting ^b   Schwager, Susan ^b   Litzow, Mark R ^b   Hogan, William J ^b   Tefferi, Ayalew ^b  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LENALIDOMIDE; POMALIDOMIDE; PREDNISONE; THALIDOMIDE;

ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LOW DRUG DOSE; MALE; MULTIPLE CYCLE TREATMENT; MYELOFIBROSIS; NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEDATION; SIDE EFFECT; SPLEEN; SPLENOMEGALY; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; TREATMENT WITHDRAWAL;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; ANTI-INFLAMMATORY AGENTS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PREDNISOLONE; PRIMARY MYELOFIBROSIS; THALIDOMIDE;

EID: 75449087842     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21598     Document Type: Article

References (16)

1. Mesa RA, Niblack J, Wadleigh M, et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): An international internet-based survey of 1179 MPD patients. Cancer 2007;109:68-76.
2. Cervantes F, Dupiez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009;113:2895-2901.
3. Dupriez B, Morel P, Demory JL, et al. Prognostic factors in agnogenic myeloid metaplasia: A report on 195 cases with a new scoring system [see comments]. Blood 1996;88:1013-1018.
4. Cervantes F, Alvarez-Larran A, Domingo A, Arellano-Rodrigo E, Montserrat E. Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: Long-term results in 30 patients. Br J Haematol 2005;129:771-775.
5. Huang J, Tefferi A. Erythropoiesis stimulating agents have limited therapeutic activity in transfusion-dependent patients with primary myelofibrosis regardless of serum erythropoietin level. Eur J Haematol 2009;83:154-155.
6. Huang J, Li CY, Mesa My, et al. Risk factors for leukemic transformation in patients with primary myelofibrosis. Cancer 2008;112:2726-2732.
7. Barosi G, Elliot MA, Canepa L, et al. Thalidomide in Myelofibrosis with Myeloid Metaplasia: A Pooled-analysis of Individual Patient Data from Five Studies. Leuk Lymphoma 2002;43:2301-2307.
8. Mesa RA, Steensma DP, Pardaaani A, et al. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood 2003;101:2534-2541.
9. Tefferi A, Cortes J, Verstovsek S, et al. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood 2006;108:1158-1164.
10. Quintas-Cardama A, Kantarjian HM, Manshouri T, et al. Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. J Clin Oncol 2009;27:4760-4766.
11. Mesa RA, Yao X, Cripe LD, Li CY, Tefferi A, Tallman MS. Lenalidomide and prednisone for primary and post polycythemia vera/essential thrombocythemia myelofibrosis (MF): An Eastern Cooperative Oncology Group (ECOG) Phase II Trial. Blood 2008;112:1753.
12. Schey SA, Baxtlett JB, et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol 2004;22:3269-3276.
13. Tefferi A, Verstovsek S, Barosi G, et al. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol 2009;27: 4563-4569.
14. Tefferi A, Barosi G, Mesa RA, et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood 2006;108:1497-1503.
15. Tefferi A, Elliott. Serious myeloproliferative reactions associated with the use of thalidomide in myelofibrosis with myeloid metaplasia. Blood 2000;96: 4007.
16. Pardanani A. JAK2 inhibitor therapy in myeloproliferative disorders: Rationale, preclinical studies and ongoing clinical trials. Leukemia 2008;22:23-30.